CY1107383T1 - Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος - Google Patents

Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος

Info

Publication number
CY1107383T1
CY1107383T1 CY20081100371T CY081100371T CY1107383T1 CY 1107383 T1 CY1107383 T1 CY 1107383T1 CY 20081100371 T CY20081100371 T CY 20081100371T CY 081100371 T CY081100371 T CY 081100371T CY 1107383 T1 CY1107383 T1 CY 1107383T1
Authority
CY
Cyprus
Prior art keywords
physology
suspensions
solution
enzymes
compounds
Prior art date
Application number
CY20081100371T
Other languages
Greek (el)
English (en)
Inventor
John Caedmon Mckew
Steve Yik-Kai Tam
James Donald Clark
Katherine Lin Lee
Lihren Chen
Paresh Thakker
Fuk-Wah Sum
Mark Leo Behnke
Baihua Hu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of CY1107383T1 publication Critical patent/CY1107383T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20081100371T 2001-12-03 2008-03-31 Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος CY1107383T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33458801P 2001-12-03 2001-12-03
US33460501P 2001-12-03 2001-12-03
US33459101P 2001-12-03 2001-12-03
US41966402P 2002-10-18 2002-10-18
EP02786829A EP1451154B1 (en) 2001-12-03 2002-12-02 Inhibitors of cytosolic phospholipase a2

Publications (1)

Publication Number Publication Date
CY1107383T1 true CY1107383T1 (el) 2012-12-19

Family

ID=27502498

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100371T CY1107383T1 (el) 2001-12-03 2008-03-31 Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος

Country Status (24)

Country Link
EP (1) EP1451154B1 (enExample)
JP (1) JP4657605B2 (enExample)
KR (1) KR100973665B1 (enExample)
CN (1) CN100503566C (enExample)
AR (1) AR037684A1 (enExample)
AT (1) ATE384045T1 (enExample)
AU (1) AU2002351182B2 (enExample)
BR (1) BR0214672A (enExample)
CA (1) CA2469138C (enExample)
CO (1) CO5580763A2 (enExample)
CY (1) CY1107383T1 (enExample)
DE (1) DE60224707T2 (enExample)
DK (2) DK1892239T3 (enExample)
EC (1) ECSP045131A (enExample)
ES (2) ES2401454T3 (enExample)
HU (1) HUP0402577A3 (enExample)
IL (2) IL162052A0 (enExample)
IN (1) IN2005KO00312A (enExample)
NO (1) NO327256B1 (enExample)
NZ (1) NZ533269A (enExample)
PL (1) PL370445A1 (enExample)
PT (1) PT1451154E (enExample)
TW (1) TWI334778B (enExample)
WO (1) WO2003048122A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
CN100548981C (zh) 2003-11-17 2009-10-14 惠氏公司 制备n-取代的邻苯二甲酰亚胺的方法
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR048239A1 (es) 2004-02-25 2006-04-12 Wyeth Corp Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
ES2348920T3 (es) 2005-04-13 2010-12-17 Astion Development A/S Agonistas de adrenoceptores beta-2 para el tratamiento de enfermedades del tejido conectivo de la piel.
TW200718687A (en) * 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
RU2466983C2 (ru) * 2005-07-21 2012-11-20 Вайет Способ синтеза сульфонилгалогенидов и сульфонамидов из солей сульфоновых кислот
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
FR2899471A1 (fr) * 2006-04-06 2007-10-12 Pasteur Institut Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement des maladies respiratoires
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
EP2077825A2 (en) * 2006-10-31 2009-07-15 Wyeth Liquid formulations of phospholipase enzyme inhibitors
RU2009116423A (ru) * 2006-10-31 2010-12-10 Вайет (Us) Композиции ингибиторов фермента фосфолипазы
JP5164972B2 (ja) * 2007-03-29 2013-03-21 第一三共株式会社 cPLA2阻害活性を有するインドール誘導体およびその用途並びに製造方法
JP5198560B2 (ja) 2008-04-28 2013-05-15 旭化成ファーマ株式会社 フェニルプロピオン酸誘導体及びその用途
WO2011047156A1 (en) * 2009-10-15 2011-04-21 Hercules Technology Management Co V, Inc. Sepiapterin reductase inhibitors for the treatment of pain
WO2012031763A1 (en) 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
EA003876B1 (ru) * 1998-02-25 2003-10-30 Дженетикс Инститьют, Ллс Ингибиторы фосфолипазных ферментов
EE200000486A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal

Also Published As

Publication number Publication date
DE60224707T2 (de) 2009-02-26
JP2005515997A (ja) 2005-06-02
DE60224707D1 (de) 2008-03-06
PT1451154E (pt) 2008-04-21
IL162052A (en) 2013-04-30
ES2300490T3 (es) 2008-06-16
ATE384045T1 (de) 2008-02-15
DK1451154T3 (da) 2008-05-19
HUP0402577A3 (en) 2011-05-30
TW200301695A (en) 2003-07-16
AU2002351182A1 (en) 2003-06-17
CO5580763A2 (es) 2005-11-30
KR20050044661A (ko) 2005-05-12
HUP0402577A2 (hu) 2005-03-29
CN1617855A (zh) 2005-05-18
CA2469138A1 (en) 2003-06-12
AR037684A1 (es) 2004-12-01
KR100973665B1 (ko) 2010-08-04
DK1892239T3 (da) 2013-03-25
ECSP045131A (es) 2004-07-23
ES2401454T3 (es) 2013-04-19
HK1065799A1 (en) 2005-03-04
NZ533269A (en) 2006-03-31
EP1451154A2 (en) 2004-09-01
TWI334778B (en) 2010-12-21
IL162052A0 (en) 2005-11-20
NO20042679L (no) 2004-06-25
CN100503566C (zh) 2009-06-24
PL370445A1 (en) 2005-05-30
WO2003048122A3 (en) 2003-09-18
WO2003048122A2 (en) 2003-06-12
HK1113798A1 (en) 2008-10-17
JP4657605B2 (ja) 2011-03-23
CA2469138C (en) 2012-04-17
IN2005KO00312A (enExample) 2015-08-14
BR0214672A (pt) 2004-10-19
AU2002351182B2 (en) 2009-01-15
NO327256B1 (no) 2009-05-25
EP1451154B1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE50310516D1 (de) Fredericamycin-derivate
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CY1110171T1 (el) Ιατρικη χρηση αναστολεων γλουταμινικων και γλουταμικων κυκλασων για θεραπεια της ασθενειας του alzheimer και του συνδρομου down
CY1108813T1 (el) Αναστολεις κινασων τυροσινης
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
CY1107069T1 (el) Χρηση των αναστολεων της cox-2 σαν ανοσοδιεγερτες στη θεραπεια του hiv ή του aids
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
SE0101932D0 (sv) Pharmaceutical combinations
CY1110415T1 (el) Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs)
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
PA8466101A1 (es) Agentes terapeuticos
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE69930844D1 (de) Inhibitoren von mycobakterien